Bevacizumab in non-small-cell lung cancer: a review (Q37931886)

25 August 2017

1 reference

title

Bevacizumab in non-small-cell lung cancer: a review (English)

1 reference

25 August 2017

1 reference

1 reference

David Planchard

1

1 reference

25 August 2017

publication date

1 August 2011

1 reference

Expert Review of Anticancer Therapy

25 August 2017

published in

1 reference

25 August 2017

volume

11

1 reference

25 August 2017

issue

8

1 reference

25 August 2017

page(s)

1163-1179

1 reference

25 August 2017

cites work

Cancer statistics, 2010

1 reference

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

Clinical translation of angiogenesis inhibitors

21 January 2018

1 reference

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis

21 January 2018

1 reference

Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody

21 January 2018

1 reference

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

21 January 2018

1 reference

Clinical pharmacokinetics of bevacizumab in patients with solid tumors

21 January 2018

1 reference

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

21 January 2018

1 reference

Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer

21 January 2018

1 reference

Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer

21 January 2018

1 reference

Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer

21 January 2018

1 reference

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

21 January 2018

1 reference

Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors.

21 January 2018

1 reference

Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by mainte

21 January 2018

1 reference

Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

21 January 2018

1 reference

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.

21 January 2018

1 reference

The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

21 January 2018

1 reference

Oncogenes and angiogenesis: signaling three-dimensional tumor growth

21 January 2018

1 reference

The role of the EGFR signaling in tumor microenvironment.

21 January 2018

1 reference

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs

21 January 2018

1 reference

First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging.

21 January 2018

1 reference

Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics

21 January 2018

1 reference

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

21 January 2018

1 reference

Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen

21 January 2018

1 reference

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

21 January 2018

1 reference

Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.

21 January 2018

1 reference

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

21 January 2018

1 reference

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.

21 January 2018

1 reference

Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL).

21 January 2018

1 reference

Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer

21 January 2018

1 reference

Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Tri

21 January 2018

1 reference

Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab

21 January 2018

1 reference

Value of combined androgen blockade in the neoadjuvant treatment of localized prostate cancer: the jury must remain out.

21 January 2018

1 reference

Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases

21 January 2018

1 reference

Bevacizumab safety in patients with central nervous system metastases

21 January 2018

1 reference

Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants.

21 January 2018

1 reference

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

21 January 2018

1 reference

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

21 January 2018

1 reference

A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers

21 January 2018

1 reference

Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study

21 January 2018

1 reference

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer

21 January 2018

1 reference

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer

21 January 2018

1 reference

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

21 January 2018

1 reference

Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.11.80

1 reference

25 August 2017

1 reference